



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2017-18  
Date: 18<sup>th</sup> August, 2017

To,  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001  
BSE CODE - 524348  
BSE ID - AARTIDRUGS

National Stock Exchange of India  
Limited  
"Exchange Plaza",  
Bandra - Kurla Complex,  
Bandra(E), Mumbai - 400 051  
NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting held today i.e. 18<sup>th</sup> August, 2017 pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Friday, 18<sup>th</sup> August, 2017 had *inter-alia* considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter ended 30<sup>th</sup> June, 2017. Accordingly, please find enclosed herewith Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30<sup>th</sup> June, 2017 along with the report of the Statutory Auditors.

The meeting commenced at 12 noon and concluded at 1.50 p.m.

The above is for your kind information and records. You are requested to acknowledge the receipt.

Thanking you,  
Yours faithfully,  
For Aarti Drugs Limited

*V. S. Ranade*

Vibhav S. Ranade  
Company Secretary & Compliance Officer



Encl: A/A



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

AARTI DRUGS LIMITED					
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUN, 2017					
(Rs. in lakhs except for share data)					
Sr. No.	Particulars	Standalone		Consolidated	
		Quarter Ended		Quarter Ended	
		30th Jun 2017 (Audited)	30th Jun 2016 (Audited)	30th Jun 2017 (Audited)	30th Jun 2016 (Audited)
I	Revenue from operations (Gross Sales)	24,826	29,484	27,720	31,549
II	Other income	6	13	7	32
III	Total Income ( I + II )	24,832	29,497	27,726	31,580
IV	Expenses :				
	(a) Cost of materials consumed	18,536	19,559	20,617	20,950
	(b) Purchase of stock-in-trade	824	434	1,137	789
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,389)	(2,417)	(5,533)	(2,605)
	(d) Excise duty/taxes on goods sold	1,920	2,586	1,894	2,399
	(e) Employee benefits expense	1,189	1,150	1,360	1,261
	(f) Finance costs	846	948	894	996
	(g) Depreciation and amortisation expense	926	920	981	962
	(h) Other expenses	4,429	3,804	4,705	3,980
	Total expenses (IV)	23,280	26,984	26,054	28,732
V	Profit before exceptional items and tax (III - IV)	1,552	2,514	1,672	2,849
VI	Exceptional items	-	-	-	-
VII	Profit before tax (V - VI)	1,552	2,514	1,672	2,849
VIII	Tax Expenses :				
	Provision for taxation - Current	370	640	398	713
	- MAT credit entitlement	-	-	(4)	-
	- Earlier year	-	-	-	-
	Provision for deferred taxation	125	140	140	148
	Total tax expenses (VIII)	495	780	534	861
IX	Profit/(Loss) for the period from continuing operations( VII - VIII )	1,057	1,734	1,138	1,988
X	Profit / (Loss) form discontinuing operations	-	-	-	-
XI	Tax expenses of discontinuing operations	-	-	-	-
XII	Profit /(Loss) from discontinuing operations ( X - XI )	-	-	-	-
XIII	Profit / (Loss) for the period ( IX - XII )	1,057	1,734	1,138	1,988
XIV	Other Comprehensive Income	-	2	-	2
XV	Total Comprehensive Income for the period (XIII+XIV)	1,057	1,736	1,138	1,989
XVI	Earning per equity share ( in Rs.)				
	(1) Basic	4.43	7.16	4.77	8.21
	(2) Diluted	4.43	7.16	4.77	8.21

**Notes :**

- The above results for the Quarter ended 30th June, 2017 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 18th August, 2017.
- The company has adopted Ind-AS from 1st April, 2017 and accordingly this financial results have been prepared in accordance with the Ind- AS prescribed under Section 133 of the Companies Act, 2013 . Consequently, the results for the quarter ended on 30th June, 2016 have been restated to comply with Ind-AS .Reconciliation of Net Profit reported under previous IGAAP and restated under Ind-AS is as under:

Particulars	(Rs. In Lakhs)	
	Standalone	Consolidated
	30th Jun 2016 (Audited)	30th Jun 2016 (Audited)
Net Profit as per previous IGAAP	1,734	1,994
Other Ind-AS Adjustment		(7)
Other Comprehensive Income (Net of tax)		
-Impact of measuring investments at fair value-	2	2
Total Comprehensive Income as per Ind-AS	1,736	1,989

- Company is operating as a single segment company, engaged in pharmaceutical business.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

For AARTI DRUGS LIMITED

Prakash M. Patil  
CHAIRMAN & MANAGING DIRECTOR

Place: Tarapur  
Date: 18th August, 2017



**gokhale & sathe**

(regd.)

chartered accountants

308/309, udyog mandir no. 1,  
7-c, bhagoji keer marg,  
mahim, mumbai 400 016.

**Auditors' Report on Quarterly Standalone Financial Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To

The Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly standalone financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended June 30, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly standalone financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (AS) 34 "Interim Financial Reporting", prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results:

- (i) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5<sup>th</sup> July 2016 in this regard; and
- (ii) give a true and fair view of the net profit, total comprehensive income and other financial information for the quarter ended June 30, 2017.

For GOKHALE & SATHE  
CHARTERED ACCOUNTANTS  
Firm Registration No.: 103264W

CA TEJAS PARIKH  
PARTNER  
M. No. 123215  
Place: Tarapur, District Palghar  
Date: 18<sup>th</sup> August 2017





**gokhale & sathe**

(regd.)

chartered accountants

308/309, udyog mandir no. 1,  
7-c, bhagoji keer marg,  
mahim, mumbai 400 016.

**Auditors' Report on Quarterly Consolidated Financial Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED ("the Company") for the quarter ended June 30, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly consolidated financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid Indian Accounting Standard (AS) 34 "Interim Financial Reporting", prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly consolidated financial results:

- (i) include the quarterly financial results of its only subsidiary, Pinnacle Life Science Private Limited
- (i) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5<sup>th</sup> July 2016 in this regard; and
- (ii) give a true and fair view of the consolidated net profit, total comprehensive income and other financial information for the quarter ended June 30, 2017.

For GOKHALE & SATHE  
CHARTERED ACCOUNTANTS  
Firm Registration No.: 103264W

CA TEJAS PARIKH  
PARTNER

M. No. 123215

Place: Tarapur, District Palghar

Date: 18<sup>th</sup> August 2017

